

Contents

Foreword	xiii
Preface	xv
Acknowledgements	xvii
Abbreviations	xix
About the Companion Website	xxiii
1 Background to Molecular and Cellular Toxicology	1
1.1 What do we mean by molecular and cellular toxicology?	1
1.2 Tissues and their maintenance	2
1.2.1 Stem cells	3
1.3 Tissue damage	4
1.3.1 Consequences of tissue injury	4
1.3.2 Reversible changes in cells and tissues	6
1.3.3 Irreversible changes in cells and tissues	7
1.4 Tissue responses to injury	7
1.4.1 Oxidative stress	7
1.4.2 Necrosis and apoptosis	10
1.4.3 Neoplasia	13
1.4.4 The initiation–promotion paradigm	13
1.5 Key concepts in toxicology	23
1.5.1 Risk and hazard	23
1.5.2 Variability and uncertainty	25
1.5.3 Threshold and non-threshold dose responses	26
1.5.4 The regulatory context	28
1.5.5 Limitations of whole animal studies	29
1.5.6 Use of human tissues in toxicology	31

1.6	Summing up	33
	Self-assessment questions	33
	Background Reading	34
	References	34
2	Individual Susceptibility to Toxic Chemicals	37
2.1	Introduction	37
2.2	Toxicogenetics and toxicogenomics	38
2.3	Genotyping and phenotyping	39
2.3.1	Genotyping	40
2.3.2	Phenotyping	43
2.3.3	Correlating genotype and phenotype	44
2.4	Polymorphic xenobiotic metabolism	45
2.4.1	Polymorphic xenobiotic metabolising enzymes	49
2.4.2	The role of xenobiotic metabolising polymorphisms in susceptibility to toxic agents	50
2.5	Study numbers and effect size	60
2.6	Recent developments	62
2.6.1	Genome-wide association studies	62
2.6.2	Collaborative programmes	64
2.7	The UK Biobank	69
2.8	Conclusions	71
	Self-assessment questions	72
	Background Reading	72
	References	73
3	'Omics Techniques	79
3.1	'Omics and bioinformatics	79
3.2	Transcriptomics	80
3.2.1	Methodology	80
3.2.2	Proof of principle	89
3.2.3	Hepatotoxicity	91
3.2.4	Extrahepatic toxicity	96
3.3	Proteomics	97
3.3.1	Methodology	98
3.4	Metabolomics/metabonomics	101
3.4.1	MS-based metabolomics	102
3.4.2	NMR-based metabolomics	106
3.5	Integrating different types of 'omics data	107
3.5.1	'Omics in drug discovery	108
3.5.2	'Omics profiles as biomarkers of toxicity	109
3.6	Remaining issues with 'omics approaches	111
3.7	Conclusions	112
	Self-assessment questions	113
	Background Reading	113
	References	113
4	<i>In Vitro</i> Methods for Predicting <i>In Vivo</i> Toxicity	117
4.1	<i>In vitro</i> toxicology	117

4.2	Tissue culture	117
4.2.1	Primary cell cultures	122
4.2.2	Established cell lines	125
4.3	Acute toxicity <i>in vitro</i>	127
4.3.1	Cytotoxicity testing	127
4.3.2	Choice of cell line	129
4.3.3	Liver	131
4.3.4	Skin	133
4.3.5	Eye	141
4.4	Repeated dose toxicity	144
4.5	Reproductive toxicity	147
4.6	Stem cell-derived systems	149
4.7	Conclusions	151
	Self-assessment questions	151
	Background Reading	152
	References	152
5	<i>In Vitro</i> Methods for Absorption, Distribution, Metabolism and Excretion	159
5.1	Why study ADME <i>in vitro</i> ?	159
5.2	Absorption	160
5.2.1	Dermal penetration	160
5.2.2	Gastrointestinal absorption	164
5.3	Distribution	171
5.3.1	Protein binding	172
5.3.2	Blood-brain barrier	172
5.3.3	Other protective barriers	176
5.4	Metabolism	176
5.4.1	Skin	177
5.4.2	Gastrointestinal tract	179
5.4.3	Liver	179
5.5	Excretion	189
5.5.1	Biliary excretion	190
5.5.2	Renal clearance	191
5.6	Conclusions	191
	Self-assessment questions	192
	References	192
6	<i>In Silico</i> Methods and Structure–Activity Relationships	199
6.1	Why <i>in silico</i> ?	199
6.2	Predicting the ADME characteristics of xenobiotics	200
6.2.1	Absorption	200
6.2.2	Distribution	206
6.2.3	Metabolism	207
6.2.4	Excretion	212
6.3	Physiologically based biokinetic modelling	212
6.4	Toxicity	221
6.4.1	Exposure modelling	222
6.4.2	Prediction of toxicity	223

6.5	Conclusions	233
	Self-assessment questions	235
	References	235
7	Transgenic Animal Models for ADME and Systemic Toxicity	241
7.1	Transgenic models and their use in toxicology	241
7.2	ADME models	242
7.2.1	Nuclear receptor models	244
7.2.2	Xenobiotic metabolism models	251
7.2.3	Drug transporter models	259
7.3	Reporter models	264
7.3.1	LacZ-based models	264
7.3.2	Green fluorescent protein-based models	267
7.3.3	Luciferase-based models	268
7.3.4	Evaluation	273
7.4	Conclusions	273
	Self-assessment questions	274
	Background Reading	274
	References	274
8	Genotoxicity and its Measurement	281
8.1	Genotoxicity testing	281
8.2	Core <i>in vitro</i> tests	282
8.2.1	The Ames test	282
8.2.2	<i>In vitro</i> gene mutation tests using mammalian cells	283
8.2.3	The <i>in vitro</i> chromosome aberration test	284
8.2.4	The <i>in vitro</i> micronucleus assay	287
8.3	Assessment of genotoxicity for regulatory purposes	291
8.4	Novel <i>in vitro</i> methods	292
8.4.1	GreenScreen HC	292
8.4.2	The Reconstructed Skin MicroNucleus assay	293
8.5	Novel <i>in vivo</i> assays for gene mutations	294
8.5.1	The Pig-A assay	294
8.5.2	<i>In vivo</i> assays using transgenic mouse models	295
8.6	DNA damage and its repair	300
8.6.1	DNA damage	300
8.6.2	DNA repair	305
8.7	Thresholds	308
8.8	Conclusions	310
	Self-assessment questions	310
	References	311
9	Genotoxicity and the Identification of Human Carcinogens	317
9.1	Introduction	317
9.2	Identification of human carcinogens	317
9.2.1	The lifetime carcinogenicity bioassay	317
9.2.2	The National Toxicology Program 2-year bioassay	318
9.3	Genetic changes in cancer	321

9.3.1	Methods for detecting activated oncogenes	324
9.3.2	<i>In vitro</i> transformation assays	324
9.3.3	<i>Ras</i> oncogene activation during tumour development	326
9.3.4	Non- <i>ras</i> oncogenes	328
9.3.5	Evaluation	329
9.4	Non-genotoxic carcinogenesis	329
9.4.1	Non-receptor-mediated mechanisms	330
9.4.2	Receptor-mediated mechanisms	331
9.4.3	When is a genotoxic carcinogen not a genotoxic carcinogen?	333
9.5	Transgenic models for short-term carcinogenicity bioassays	335
9.5.1	<i>RasH2</i>	335
9.5.2	Tg.AC	337
9.5.3	p53 models	338
9.5.4	XPC ^{-/-} , XPA ^{-/-} and XPA ^{-/-} /p53 ^{+/-} null mouse models	340
9.5.5	Comparative evaluation of models	340
9.5.6	Regulatory status	341
9.5.7	Limitations of the assays	343
9.5.8	Evaluation	344
9.6	Conclusions	345
	Self-assessment questions	346
	References	346
10	Emerging Techniques	351
10.1	What's next?	351
10.2	Novel model organisms	351
10.2.1	The zebrafish	352
10.2.2	Evaluation	358
10.3	Less invasive methods	359
10.3.1	Use of biomarkers	359
10.3.2	Liver	359
10.3.3	Kidney	367
10.3.4	Circulating mRNA biomarkers	371
10.3.5	Evaluation	373
10.4	The systems biology approach	373
10.4.1	Systems biology in toxicology	376
10.5	Collaborative programmes	381
10.5.1	Europe	381
10.5.2	USA	383
10.5.3	Evaluation	384
10.6	Final word	385
	Self-assessment questions	385
	References	385